Severe Enterocolitis Emerges as Rare but Fatal Complication of BCMA CAR-T Therapy
Key Insights
A multicenter study identified immune effector cell-associated enterocolitis (search) (IEC-EC) in 19 patients treated with ciltacabtagene autoleucel, representing a 4.3% incidence rate with delayed onset at median 81 days post-infusion.
The condition proved highly morbid with 84% experiencing grade 3 or higher symptoms, 37% mortality rate, and limited response to standard immunosuppressive treatments including corticosteroids (search) and infliximab.
FDA adverse event data analysis revealed IEC-EC reports exclusively associated with ciltacabtagene autoleucel among all approved CAR-T therapies, suggesting construct-specific toxicity mechanisms.
A new analysis of patients treated with the BCMA (search)-directed CAR-T therapy ciltacabtagene autoleucel has revealed a previously underrecognized but potentially fatal complication: immune effector cell-associated enterocolitis (search) (IEC-EC). The multicenter case series, published in Blood Cancer Journal, documents 19 patients who developed this severe gastrointestinal toxicity, representing an estimated incidence of 4.3% among treated patients.
Late-Onset Gastrointestinal Toxicity with High Mortality
The study tracked patients treated with commercial ciltacabtagene autoleucel from April 2022 to December 2024, with a median follow-up of 473 days. IEC-EC presented as a delayed complication, with median onset of diarrhea (search) occurring 81 days after CAR-T infusion, ranging from 24 to 211 days post-treatment.
The severity of this complication was striking: 84% of patients experienced grade 3 or higher diarrhea (search) and colitis (search), while only 16% had grade 2 symptoms. Impaired bowel integrity occurred in 32% of patients, including pneumatosis intestinalis (search) in four cases and bowel perforations in two patients. The overall mortality rate reached 37%, with five patients dying specifically from IEC-EC-related complications such as perforation or infection.
Treatment Resistance and Limited Therapeutic Options
Standard immunosuppressive approaches showed disappointing efficacy. Among the 11 patients who received systemic corticosteroids (search), only one achieved symptomatic improvement. Four steroid-refractory patients were treated with infliximab, with only two showing improvement to grade 1 symptoms. Other treatments included budesonide in nine patients and octreotide in two, with variable results.
Total parenteral nutrition was required in 47% of patients, with clinical benefit observed in seven cases, underscoring the severity of gastrointestinal dysfunction. At last follow-up, only 37% achieved complete resolution of symptoms after a median of 101 days, while 37% continued to experience grade 2 or higher symptoms.
Unique Association with Ciltacabtagene Autoleucel
A separate analysis of FDA Adverse Event Reporting System (FAERS) data revealed a striking pattern: among all six FDA-approved CAR-T cell therapies, only ciltacabtagene autoleucel showed reports of immune-mediated enterocolitis. The analysis identified 31 cases with a reporting odds ratio of 83.65, indicating a strong association that appears unique among approved CAR-T products.
Notably, no reports were found for idecabtagene vicleucel, another BCMA (search)-targeting therapy, despite both targeting the same antigen. This suggests that construct-specific differences may contribute to IEC-EC risk. Ciltacabtagene autoleucel contains two scFv binding domains conferring higher binding avidity with target cells, which may explain the differential toxicity profile.
Pathophysiology and Clinical Features
The pathophysiology involves direct infiltration of CAR-T cells into gut mucosa, specifically the lamina propria and epithelium. Tissue assays in four cases demonstrated the presence of CAR+ T cells in gastrointestinal biopsies. Histopathologic examination revealed cryptitis and crypt apoptosis in 74% of patients, mucosal ulcerations in 26%, and lymphocytic infiltrates in 26%.
The clinical presentation often included upper and lower gastrointestinal involvement in 68% of patients, with frequent corticosteroid resistance and mucosal T-cell infiltration suggesting an immunopathologic profile distinct from checkpoint inhibitor colitis (search). Delayed neurotoxicity preceded diarrhea (search) onset in 26% of patients, including cranial nerve palsies and Parkinsonism.
Implications for Clinical Practice
The findings highlight the need for enhanced vigilance in monitoring patients receiving BCMA (search) CAR-T therapy, particularly given the delayed onset and severity of IEC-EC. The syndrome's resistance to standard immunosuppressive treatments and high mortality rate underscore the urgency for developing targeted interventions.
As BCMA (search) CAR-T therapy moves earlier in treatment paradigms, timely recognition becomes critical. The researchers recommend endoscopic evaluation, including TCR clonality studies, when biopsies reveal T-cell infiltrates to distinguish reactive from neoplastic processes.
The study's limitations include its retrospective nature and inability to identify clear predictive factors for IEC-EC development. However, the consistent findings across multiple centers and the unique association with ciltacabtagene autoleucel in national adverse event data provide compelling evidence for this emerging safety signal.
Future research priorities include elucidating the mechanisms driving IEC-EC, identifying predisposing factors and biomarkers for early detection, and developing optimized treatment strategies to enhance the safety profile of BCMA (search)-directed therapies.